The first biosimilar in MS: a practical discussion to the future of MS treatment
13 May 2024
About the event
An engaging webinar to discuss the launch of the first biosimilar in neurology; a natalizumab biosimilar for treatment of multiple sclerosis (MS). Learn from world-renowned expert neurologists Dr Agne Straukiene and Professor Gavin Giovannoni as they discuss the value and practical implementation of biosimilars in neurology. Understand the history of biosimilars; the science underpinning their approval; and gain insights into the benefits of biosimilars for the UK healthcare system. Our experts will also explore the challenges anticipated with biosimilar use; the importance of patient communication and the patient perspective for implementation in clinical practice.
Sandoz is a global leader in generic pharmaceuticals and biosimilars and a division of the Novartis Group. Our purpose is Pioneering Access by developing novel approaches to help people around the world access high-quality medicine and support the UK's growing healthcare needs.
